Weight loss effect of liraglutide in real-life: the experience of a single Italian obesity center
- PDF / 858,367 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 15 Downloads / 172 Views
ORIGINAL ARTICLE
Weight loss effect of liraglutide in real‑life: the experience of a single Italian obesity center F. Ferrari1 · P. Fierabracci1 · G. Salvetti1 · R. Jaccheri1 · J. Vitti1 · G. Scartabelli1 · A. Meola1 · S. Magno1 · G. Ceccarini1 · F. Santini1 Received: 19 May 2020 / Accepted: 11 June 2020 © Italian Society of Endocrinology (SIE) 2020
Abstract Purpose Several randomized controlled clinical trials (RCCTs) have shown that the use of Liraglutide (L) in addition to diet and exercise in patients with obesity or overweight (OO), compared to dietary behavioral changes alone, leads to a significantly greater weight loss. This retrospective study aimed at evaluating the effectiveness of L therapy in a real-life setting. Methods 93 consecutive non-diabetic OO, referring to a single Obesity Center, started L therapy from October 2016 to December 2018: 21/93 OO discontinued the treatment within 90 days for various reasons. 72/93 OO (55 females, 17 males), mean ± SD age 49 ± 12.5 years (18–78) and mean body mass index 39.1 ± 5.8 (28.3–55.3) were included for further analysis. 60/72 OO reached the final dose of 3.0 mg/day. Results Mean weight loss was 7.1% in the OO who reached the dose of 3.0 mg; 68.3%, 20.0% and 10.0% of OO lost ≥ 5%, 10% and 15% of body weight, respectively. A linear correlation between early and final weight loss was found. Moreover, we observed a significant reduction of mean systolic and diastolic blood pressure and a significant increase of mean heart rate. The overall incidence of side effects was 18.3% (17/93). Conclusion L treatment of OO in a real life setting yielded results comparable to those reported by the major RCCTs. Combining the results of RCCTs with the observations from real life may increase their power and overcome their respective limitations. Keywords Obesity · Obesity therapy · Liraglutide · Real life experience · Weight loss
Introduction Obesity is characterized by an excessive accumulation of body fat, to such an extent that it represents a threat to health [1–3]. Weight gain occurs when food intake exceeds energy expenditure, and obesity takes place when a new equilibrium is established in the presence of a supernormal amount of adipose stores. Substantial differences in the individual ability to regulate the reciprocal interplay between eating behavior and energy requirements explain the propensity of each subject toward the development of obesity [4]. In Europe, approximately 50% of the adults are overweight or obese [5]. In Italy, in 2018, the cumulative
* F. Santini [email protected] 1
Obesity and Lipodystrophy Center, Endocrinology Unit, University Hospital of Pisa, Pisa, Italy
prevalence of overweight and obesity in the adult population has been estimated as high as 46.1% [6]. The first approach for the management of obesity is lifestyle intervention; when indicated, pharmacological therapy and bariatric surgery have to be considered in order to obtain a substantial and durable weight loss [7, 8]. In 2015 Liraglutide (L) at a daily
Data Loading...
